Product Description
Mechanisms of Action: pepsin Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Germany | India | Korea | Mexico | Peru | Spain | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: XiAn Hospital of Traditional Chinese Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR-OQR-14004879 | N/A |
Recruiting |
Barrett Esophagus |
2018-10-30 |
|
ChiCTR-IPR-15005905 | N/A |
Not yet recruiting |
Gastritis |
2017-07-01 |